Evidence map›Paper›PMID 37656721›Full record

SynthesisPloS one2023

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis.

Kevin R Bainey, Guillaume Marquis-Gravel, Blair J MacDonald, David Bewick, Andrew Yan, Ricky D Turgeon

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. [Efficacy and safety of dual anti-platelet aggregation short post-pharmacologic stent].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. How to undertake procedures while on antiplatelet agents: a hematologist's view.Research and practice in thrombosis and haemostasis · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Kevin R BaineyMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta.
Guillaume Marquis-GravelMontreal Heart Institute, Université de Montréal, Montreal, Quebec.
Blair J MacDonaldFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia.ORCID 0000-0002-4666-1790
David BewickNew Brunswick Heart Center, Horizon Health Network, Saint John, New Brunswick.
Andrew YanDivision of Cardiology, Canadian Heart Research Centre and Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario.
Ricky D TurgeonFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia.ORCID 0000-0002-3967-1528
University of British Columbia · CAHorizon Health Network · CAMontreal Heart Institute · CASt. Michael's Hospital · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI.

methodsWe searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model.

resultsFrom 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients.

conclusionsIn HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.

Indexed as

Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsDual Anti-Platelet TherapyHemorrhageHumansMEDLINEPlatelet Aggregation Inhibitors

Identifiers

PMID37656721
PMCPMC10473507
OpenAlexW4386362030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.